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sooner than brachiocephalic fistulas and one month later thanComparison of transposed brachiobasilic fistulas to upper arm
upper arm grafts.grafts and brachiocephalic fistulas.
Conclusions. Transposed brachiobasilic fistulas provide cu-Background. Renewed interest in transposed brachiobasilic
mulative patency equivalent to upper arm grafts and brachio-fistulas has occurred since the release of the National Kidney
cephalic fistulas. They are less likely to thrombose and becomeFoundation–Dialysis Outcomes Quality Initiative (NKF-DOQI)
infected than upper arm grafts. Compared with brachiocephalicguidelines because it is an alternative method to achieve an
fistula, they are more likely to mature but are at increased risk ofupper arm fistula in patients who cannot achieve a functional
thrombosis after maturation. Transposed brachiobasilic fistulasbrachiocephalic fistula. The objective of this study was to com-
should be considered before placing an upper arm graft forpare outcomes among transposed brachiobasilic fistulas, upper
patients that cannot achieve a functional brachiocephalic fistula.arm grafts, and brachiocephalic fistulas.
Methods. A cohort of patients with upper arm accesses was
retrospectively identified. Access outcomes were determined
from medical records and contact with physicians, dialysis pro- The National Kidney Foundation–Dialysis Outcomes
viders, and patients. Primary outcome was thrombosis-free sur- Quality Initiative (NKF-DOQI) guidelines for vascular
vival. Secondary outcomes were primary failure, time to use, access recommend that the prevalence of native arterio-risk of catheter-related bacteremia, need for intervention, inci-
venous fistulas be increased in the United States. Nativedence of access-related complications, cumulative, and func-
fistulas should be attempted in at least 50% of new hemo-tional patency. Group differences in age, sex, race, diabetes, pe-
ripheral vascular disease, and number of previous accesses dialysis patients so that eventually 40% of end-stage
were adjusted for in the analysis where appropriate. renal disease (ESRD) patients will be dialyzed through
Results. Transposed brachiobasilic fistulas, upper arm grafts, a native fistula [1]. However, attempting fistulas in a
and brachiocephalic fistulas were compared in 59, 82, and 56 broader range of patients may not directly increase thepatients, respectively. Compared with transposed brachioba-
prevalence if the likelihood of failure also increases. Forsilic fistulas, upper arm grafts were more likely to thrombose
example, a recent study in a primarily African Americanwith an adjusted relative risk (RR) of 2.6 (95% CI, 1.3 to 5.3)
excluding primary failures and 1.6 (95% CI, 1.0 to 2.7) when population reported that the incidence of primary failure
accounting for the lower risk of primary failure for grafts. of radiocephalic and brachiocephalic fistulas was 66 and
Transposed brachiobasilic fistulas also required less interven- 41%, respectively, when more fistulas were attempted [2].
tion (0.7 vs. 2.4 per access-year, P  0.01) and were less likely One approach to increase fistulas is to create a trans-to become infected (0 vs. 13%, P  0.05) than grafts. Mature
posed brachiobasilic fistula when a brachiocephalic fistulabrachiocephalic fistulas were less likely to fail (RR 0.3, 95%
is not possible. This type of fistula is created by dissecting,CI, 0.1 to 1.0) and showed a trend for less thrombosis (RR 0.3,
0.1 to 1.1) than mature brachiobasilic fistulas. There was no mobilizing, and tunneling the basilic vein in the upper
significant difference in cumulative patency (failure-free sur- arm. The operation is time consuming, is technically chal-
vival) among the three types of access if primary failure was lenging, and has increased perioperative morbidity com-
included at the median follow-up of 594 days. Transposed pared with creation of the traditional brachiocephalicbrachiobasilic fistulas provided catheter-free access one month
fistula. The advantage of using the basilic vein is its large
size and deep location in the arm. The deep location
usually protects the vein from venipuncture and subse-Key words: dialysis access, arteriovenous fistula, shunt, hemodialysis,
thrombosis, native fistula, end-stage renal disease. quent scarring. The superficial tunneling may allow easier
cannulation of the fistula once mature. Although DagherReceived for publication January 30, 2001
et al introduced this procedure in 1976 [3], there is re-and in revised form April 10, 2001
Accepted for publication April 19, 2001 newed interest in the technique since the NKF-DOQI
guidelines were published [4] which recommend at- 2001 by the International Society of Nephrology
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tempting either a transposed brachiobasilic fistula or a used to image the basilic vein. Venography was generally
graft if a primary radiocephalic or brachiocephalic fistula avoided due to concerns of phlebitis. General anesthetic
is not possible. or a regional block was usually used during creation of a
Studies that compare brachiobasilic fistulas with upper transposed brachiobasilic fistula. The incision was made
arm grafts have generally found improved primary pat- from the forearm to the axilla along the course of the
ency, cumulative patency, and less risk of infection for basilic vein. The basilic vein was identified and carefully
fistulas, but mixed results for other complications [5, 6]. dissected to avoid damage to the brachial plexus, median
One study that compared brachiobasilic fistulas to brach- antebrachial cutaneous nerve, and the brachial artery.
iocephalic fistulas found increased primary failure and Vein side branches were ligated or clipped (20 or more
lower cumulative patency for brachiobasilic fistulas, but may be present). The vein was divided where it became
another found no differences [7, 8]. These studies may too small to be utilized and then mobilized toward the
be limited because of small numbers and lack of adjust- axilla. A sheathed device was used to tunnel the vein
ment for important factors, and because the race of the superficially and over the biceps using care to avoid kink-
patients was not well described. The latter limitation may ing, twisting, and disturbing the side branch clips. The
be particularly important because African Americans ap- vein was spatulated using a side branch and was anasto-
pear to be at increased risk for access failure and therefore mosed to the brachial artery using polypropylene vascu-
may particularly benefit from receiving transposed brach- lar suture. Brachiobasilic fistulas were aborted if the vein
iobasilic fistulas [9]. was small or if the artery was insufficient to supply flow
The primary objective of this study was to compare to both the access and hand. Local anesthetic or brachial
all three forms of upper arm access in a dialysis popula- plexus block was generally used during creation of grafts.
tion with a large proportion of African Americans. The Incisions were made over the medial aspect of arm proxi-
primary outcome was thrombosis-free survival, but pri- mal to the elbow and in the axilla. Six millimeter diameter,
mary failure, time to use, catheter-related bacteremia, standard wall polytetrafluoroethylene (PTFE) grafts were
intervention rate, incidence of complications, cumulative tunneled and anastomosed to the brachial artery and
patency, and functional patency were also evaluated. axillary vein in end to side fashion. Under local anesthe-
sia, brachiocephalic fistulas were constructed in the ante-
cubital fossa by anastomosing the cephalic vein to theMETHODS
brachial artery in an end to side fashion. The procedurePatient population
was aborted if the cephalic vein was found unsuitableThe cohort was retrospectively identified from the Duke
usually because of synechiae from prior venipuncture.University Medical Center Billing System using proce-
Pulse oximetry was used intraoperatively to evaluatedure codes for creation of hemodialysis grafts and fistulas
perfusion of the hand when this was in doubt. If theoccurring between December 1997 and October 1999. Op-
fistula attenuated the pulse oximetry signal significantlyerative notes were reviewed for each procedure, and only
then a distal revascularization interval ligation procedureupper arm accesses were included since brachiobasilic fis-
was considered.tulas can only be created in the upper arm. Accesses were
excluded when (1) the cephalic vein was transposed in- Definition of outcomes
stead of the basilic vein, (2) an axillary artery was used,
The primary outcome was thrombosis-free survival.(3) dialysis was discontinued before access success could
Secondary outcomes were primary failure, time to firstbe evaluated (within 3 months), or (4) patients were lost
use, catheter-related bacteremia, intervention rate (sur-to follow-up. Only one upper arm access per patient was
gical or radiological), incidence of complications, cumu-included to maintain independence of observations. Base-
lative patency (time to failure), and functional patency.line information and access outcomes were determined
Primary failure was defined as an access that failed toby review of medical records and contact with physicians,
provide reliable, catheter-free access for at least onedialysis unit nurses, and patients if needed. Patients pro-
month. Time to use was from access creation to removalvided consent if contacted. The Institutional Review
of the central venous catheter or to first needle stick ifBoard approved the protocol.
a catheter was not used. Catheter removal was usedBaseline data included patient demographics, smoking
preferentially because often a significant delay occurredhistory, diabetic status, history of peripheral vascular dis-
between first needle stick and reliable use of the access,ease, and number of previous accesses. Amputation, pe-
particularly for fistulas. Predialysis patients were ex-ripheral by-pass, or a history of gangrene or claudication
cluded from the calculation of time to use. Catheter-was considered peripheral vascular disease.
related bacteremia was defined as any bacteremia that
Surgical technique occurred after access creation that was judged to be
catheter-related after reviewing medical records. ThePreoperatively, the vascular surgeon evaluated patients
by clinical examination. Ultrasound was occasionally intervention rate was defined as the number of radiologi-
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Table 1. Baseline characteristics according to access groupcal or surgical procedures performed per access-year.
Interventions occurring at the time of access failure (for Brachiobasilic Grafts Brachiocephalic
example, failed thrombectomy) were not included. Sten- N 59 80 56
Age 53 59a 59oses were classified as anastomotic (arterial and/or ve-
Male % 59 45 59nous for grafts), venous outflow, or central vein.
Black % 68 78 66
Time to access failure (cumulative patency) was de- Diabetes % 48 69a 43
Smoking status %fined from access creation to complete failure. If a bra-
Never 42 48 39chiocephalic or brachiobasilic fistula was revised with
Former 39 39 41
PTFE, it was considered an access failure. Functional Current 19 13 20
Peripheral vascular disease 19 20 14patency was defined similar to cumulative patency but
First access % 37 34 71
subtracted the days where the access was not being used
Second access % 29 38 18 bfor dialysis. Functional patency did not include the time Third access % 34 29 11
to use or any periods where catheters were in place Time on dialysis days 683 798 198b
because the access temporarily failed. Patients with long a P  0.05 compared with brachiobasilic fistula
b P  0.01 compared with brachiobasilic fistulapredialysis periods or unreliable access (frequent revi-
sions with catheter placements) were accounted for in
this method. Primary failures were assigned a cumulative
and functional patency of zero.
and continuous variables were compared with unpairedAccesses were followed for these outcomes from cre-
t tests. All comparisons were between brachiobasilic fis-ation to termination, censor, or end of the follow-up pe-
tulas and either grafts or brachiocephalic fistulas. Two-riod. Patent accesses were censored if hemodialysis was
sided P values0.05 were considered significant. Analy-discontinued for death, transplant, transfer to peritoneal
sis was performed using the SAS system version 6.12dialysis, or recovery of renal function. Access patency
(The SAS Institute, Cary, NC, USA).was confirmed up to the time of censoring.
Statistical analysis
RESULTS
The primary outcome, thrombosis-free survival, was
Patient populationplotted using Kaplan-Meier method [10] and was com-
Review of billing records identified 212 patients withpared between brachiobasilic fistulas and grafts using
the Cox proportional hazards model [11]. Differences in upper arm accesses created from December 1997 to Oc-
thrombosis-free survival were adjusted for baseline group tober 1999 at the Duke University Medical Center. Ac-
differences and other covariates associated with outcomes. cess was excluded because the cephalic vein was trans-
The analysis was performed with and without primary posed rather than basilic (N  5), upper arm graft was
failures. A priori power calculations showed that 53 pa- looped from axillary artery to axillary vein (N  2),
tients were required in each group to have 80% power and patients died or received a transplant within three
to detect a difference in one-year thrombosis free pat- months of access creation (N  8). Eight patients were
ency of 70% for grafts and 90% for transposed brachio- lost to follow-up. Thus, outcomes were available for
basilic fistulas assuming a two-sided  of 0.05 (Stplan 96% of the cohort. The median follow-up for transposed
Software, M.D. Anderson Cancer Center, Houston, TX, brachiobasilic fistulas, brachiocephalic fistulas, and up-
USA). We assumed there would be no difference in per arm grafts was 505 (range of 327 to 807), 598 (range
thrombosis-free survival between brachiobasilic and bra- of 407 to 934) and 705 (range 427 to 934) days, respec-
chiocephalic fistulas.
tively. Seventy-one percent of the patients were African
Similar methods were used to compare failure-free
American. Patients with brachiobasilic fistulas weresurvival (cumulative patency) and functional patency.
younger and were less likely to be diabetic than patientsOne-year survival also is reported for these outcomes.
with upper arm grafts (Table 1). Brachiocephalic fistulasThe risk of primary failure was modeled with logistic
were more likely to be placed in patients on dialysis forregression. Intervention rates were calculated for each
less time and with fewer previous failed accesses thansubject, and the groups were compared using the Wil-
patients with transposed brachiobasilic fistulas. Therecoxon rank-sum test (rates were not normally distrib-
was a trend for males to receive brachiobasilic fistulasuted). Mean intervention rates are given for descriptive
compared with grafts and for younger patients to receivepurposes since many median rates were zero. Complica-
brachiobasilic compared to brachiocephalic fistulas. Notions, including stenoses, were classified as present or
significant differences in the race, smoking status, orabsent regardless of the number of times they occurred.
presence of peripheral vascular disease occurred amongDifferences in proportions were compared with chi-
square tests (or Fisher’s exact tests where appropriate), the groups.
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Fig. 1. Thrombosis-free survival of brachio-
basilic fistulas (dotted line), brachiocephalic
fistulas (dashed line), and upper arm grafts
(solid line) excluding (A) and including primary
failure (B). The adjusted relative risk of throm-
bosis excluding primary failure for grafts was
2.6 (95% CI, 1.3 to 5.3) and for brachiocepha-
lic fistulas was 0.3 (95% CI, 0.1 to 1.1) com-
pared with brachiobasilic fistulas. The relative
risk of thrombosis or primary failure for grafts
and brachiocephalic fistulas was 1.6 (95% CI,
1.0 to 2.7) and 1.1 (95% CI, 0.4 to 2.8), respec-
tively.
Table 2. Outcomes for brachiobasilic fistulas, grafts, andThrombosis-free survival
brachiocephalic fistulas
Excluding primary failures, brachiobasilic fistulas were
Brachiobasilic Grafts Brachiocephalicsignificantly less likely to thrombose than grafts (Fig. 1A).
N 59 80 56The relative risk (RR) for thrombosis adjusted for sex,
Follow-up days
age, race, diabetes, number of previous accesses, and (range) 505 (327–807) 705 (427–932) 598 (407–934)
Thrombosis-free atperipheral vascular disease was 2.6 (95% CI, 1.3 to 5.3)
1 year % 77 50b 93bfor grafts compared to brachiobasilic fistulas. Mature Patent at 1 year % 64 62 64
brachiocephalic fistulas (excluding primary failure) had Primary failure % 21 15 32
Time to use days 100 62a 122an adjusted RR of thrombosis of 0.3 (95% CI, 0.1 to 1.1)
Cathetercompared with transposed brachiobasilic fistulas. The bacteremia % 26 19 37
adjusted RR for thrombosis was 2.0 (95% CI, 1.0 to 4.3) a P  0.01 compared to brachiobasilic fistulas
b Excluding primary failure. The adjusted relative risk of thrombosis was 2.6and 2.0 (95% CI, 1.0 to 4.0) for black patients and pa-
(95% CI, 1.3–5.3) for grafts and 0.3 (95% CI, 0.1–1.1) for brachiocephalic fistulatients with peripheral vascular disease, respectively. Ex- compared with brachiobasilic fistulas based on the Cox proportional hazards
analysis adjusting for age, sex, diabetes, number of previous accesses, and pres-cluding primary failure, the one-year thrombosis-free
ence of peripheral vascular disease.survival was 77, 50, and 93% for brachiobasilic fistulas,
upper arm grafts, and brachiocephalic fistulas, respec-
tively (Table 2). The difference between the two types of fistulas became
The data were reanalyzed using the combined end- nonsignificant (RR for brachiocephalic fistula 1.1, 95%
point of primary failure or thrombosis because often CI 0.4 to 2.8).
thrombosis was at least part of the reason for primary
Interventions and stenosisfailure (Fig. 1B). Including primary failure decreased the
RR of thrombosis or primary failure for grafts compared The differences in thrombosis-free survival were re-
flected in the intervention rates. Transposed brachiobasi-with brachiobasilic fistulas to 1.6 (95% CI, 1.0 to 2.7).
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Table 4. Non-thrombotic complications according to access typeTable 3. Intervention rates according to access type
Brachiobasilic Grafts Brachiocephalic Brachiobasilic Grafts Brachiocephalic
N 59 80 56N 59 80 56
Thrombectomy  Infection % 2 13a 2
Steal % 2 9 11revision 0.1 0.9b 0.03
Revision for non- Arm swelling % 3 11 7
Seromab % — 6a —thrombotic indication 0.1 0.1 0.2
Thrombolysis  Poor maturationc % 6 0 11
Hemorrhage % 3 1 2angioplasty 0.2 0.8b 0.0a
Fistulogram  Complications occurred at least once and required an intervention to treat.
angioplasty 0.4 0.6 0.2 a P  0.05 compared to brachiobasilic fistulas
Total 0.7 2.4b 0.4 b Seroma occurs when the graft fails to seal at the anastomosis and a transudate
of plasma collects around the graft. Also known as weeping syndromeAll intervention rates are in access-years and reported as the mean per group.
c Poor maturation denotes access that required an intervention to promotea P  0.05 compared to brachiobasilic fistulas
maturation but went on to provide functional access (excludes primary failure)b P  0.01 compared to brachiobasilic fistulas
risk of catheter-related bacteremia, but these differenceslic fistulas required less overall intervention than grafts
in infection did not reach statistical significance.because of lower rates of thrombectomy and thromboly-
sis (Table 3). No difference in the overall intervention
Nonthrombotic complications, cumulative andrate was observed between brachiobasilic and brachio-
functional patencycephalic fistulas but brachiobasilic fistulas required more
Only 2% of brachiobasilic fistulas became infectedthrombolysis with or without angioplasty.
compared with 12% of grafts (P  0.03; Table 4). SixAccess stenoses were noted at the time of angiogram
percent of transposed brachiobasilic fistulas required aperformed electively at physician request or after throm-
procedure to facilitate maturation compared with nonebosis. Anastomotic stenoses were detected in 38 of 82
of the grafts (P  0.06). Six percent of grafts and none(46%) grafts (stenosis at either the arterial or venous ana-
of the fistulas were complicated by seromas requiringstomosis), 10 of 59 (17%) brachiobasilic fistulas (P  0.01
intervention (P 0.05). The incidence of steal for brachio-compared with grafts), and none of the brachiocephalic
basilic fistulas, grafts, and brachiocephalic fistulas was 2,fistulas (P  0.01 compared with brachiobasilic fistulas).
9 and 11%, respectively (P  0.06, brachiobasilic com-Stenoses in the outflow veins were detected in 6 of 59
pared with brachiobasilic fistulas). There was no differ-(10%) brachiobasilic fistulas, 6 of 82 (10%) grafts, and 4
ence in the incidence of arm swelling or hemorrhageof 56 (5%) brachiocephalic fistulas. Central vein stenoses
among the three types of access.were found in 9 of 82 (11%) grafts, 4 of 59 (7%) brachio-
basilic fistulas, and 2 of 56 (4%) brachiocephalic fistulas. Similar to the thrombosis analysis, cumulative patency
was greatly affected by the inclusion or exclusion of
Primary failure, time to use, and primary failure (Fig. 2). If primary failure was excluded,
catheter-related bacteremia the RR of failure (adjusted for age, sex, diabetic status
The risk of primary failure for transposed brachiobasi- and number of past accesses) for grafts was 2.3 (95%
lic fistulas, grafts, and brachiocephalic fistulas was 21, 15, CI, 1.0 to 4.9) and for brachiocephalic fistulas was 0.3
and 32%, respectively (Table 2). After adjustment for (0.1 to 1.0) compared with transposed brachiobasilic fis-
differences in age, sex, diabetic status, and number of tulas. If primary failures were included, the RR of failure
past accesses, brachiocephalic fistulas showed a trend for for grafts and brachiocephalic fistulas becomes nonsig-
more primary failure than brachiobasilic fistula with a nificant at 1.3 (0.8 to 2.4) and 1.1 (95% CI, 0.6 to 2.0),
RR of 2.5 (95% CI, 0.9 to 6.4, P  0.07). Female sex respectively. Similar results were found for functional
was independently associated with primary failure with patency, which accounted for time to first use and all
a RR of 2.6 (95% CI, 1.2 to 5.6). Black race was not catheterization periods. Race was not associated with
associated with primary failure in univariate model failure in these analyses. Brachiobasilic fistulas were pa-
(RR 1.2, 95% CI 0.5 to 2.6) or when forced into the tent at the end of follow-up in 12 of 24 (50%) females
multivariable model. No statistical difference in primary and 24 of 40 (60%) black patients.
failure between brachiobasilic fistulas and grafts was ob-
served. Brachiobasilic fistulas on average provided cath-
DISCUSSIONeter-free access 100 days after creation, which was ap-
The objective of this study was to compare transposedproximately one month sooner than brachiocephalic
brachiobasilic fistulas with the two other types of hemo-fistula and one month later than grafts (P  0.01, grafts
dialysis access commonly placed in the upper arm. Thecompared with brachiobasilic fistulas). Each month of
maturation was associated with an approximately 9% advantages of transposed brachiobasilic fistulas compared
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Fig. 2. Failure-free survival (cumulative pat-
ency) of brachiobasilic fistulas (dotted line),
brachiocephalic fistulas (dashed line), and up-
per arm grafts (solid line) excluding (A) and in-
cluding primary failure (B). The adjusted rela-
tive risk of failure excluding primary failure
for grafts was 2.3 (95% CI, 1.0 to 4.9) and for
brachiocephalic fistulas was 0.3 (0.1 to 1.0) com-
pared with brachiobasilic fistulas. If primary
failures are included, the relative risk of failure
for grafts and brachiocephalic was nonsignifi-
cant compared with brachiobasilic fistulas.
with grafts are their lower risk of thrombosis, intervention, silic vein is large and tunneled superficially, it is more
likely to mature and is ready for use sooner than brachio-and infection. Accounting for the lower risk of primary
failure for grafts reduces benefits in terms of thrombosis cephalic fistulas. Brachiobasilic fistulas are less likely to
thrombose or become infected than synthetic grafts be-but it is still significant. Mature transposed brachiobasilic
fistulas are more likely to thrombose and have shorter cause they are constructed from native vessels.
Our results support other investigators who havecumulative patency than mature brachiocephalic fistulas.
However, the differences between brachiobasilic and found brachiobasilic fistulas to be at lower risk for throm-
bosis and infection compared to grafts [6] but not asbrachiocephalic fistulas become nonsignificant after ac-
counting for the higher risk of primary failure for brachio- thrombosis-free as mature brachiocephalic fistula [8]. In
contrast to previous studies, there was no difference incephalic fistulas. Transposed brachiobasilic fistulas took
approximately one month longer than grafts and one cumulative patency among the three forms of access if
primary failure is included [5, 6]. Our slightly shortermonth shorter than brachiocephalic fistulas to use; each
additional month of maturation time was associated with follow-up of 1.6 years or their excellent two-year paten-
cies of 70 to 86% may explain this disparity. However,a 9% risk of catheter-related bacteremia.
The unique outcomes of brachiobasilic fistulas appear cohort studies of at least 20 patients with brachiobasilic
fistulas report one-year, two-year, and three-year paten-to be a logical extension of the transposition process.
During transposition, the basilic vein is dissected, mobi- cies of 58 to 85%, 50 to 53%, and 43 to 57%, respectively,
which are similar to our results [12–14]. Cohort studieslized, and tunneled. This process can devascularize or kink
the venous segment, increasing the risk of stenosis and of brachiocephalic fistulas and grafts report one-year
cumulative patencies of 70 to 84% and 91%, respectivelythrombosis compared with the brachiocephalic fistula
where the vein is left in situ. This characteristic supports [15–17]. Thus, it is not clear whether any type of upper
arm access has superior cumulative patency if primarymore intensive monitoring of brachiobasilic fistulas than
brachiocephalic fistulas. On the other hand, since the ba- failure is included. Studies with longer follow-up are
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needed and we plan to continue to study this cohort, as However, brachiobasilic fistulas should be considered
it is possible that fistulas will remain patent compared second because compared with grafts, they offer similar
with continued loss of grafts over time. patency with less risk of thrombosis, intervention, and
This study also re-emphasizes the paramount impor- infection. Brachiobasilic fistulas should be monitored
tance of early access planning. Even though only upper carefully because they are at greater risk for stenosis
arm accesses were included, the time from creation to and thrombosis than brachiocephalic fistulas. Future
catheter-free use ranged from two months for grafts to studies of secondary access should be randomized if pos-
four months for brachiocephalic fistulas. These times are sible and will need long-term follow-up to determine
generally longer than other studies because they reflect whether differences in cumulative patency exist. In the
catheter removal, not first needling, for the majority of meantime, we encourage dialysis programs to offer trans-
the patients. This end point was chosen primarily because posed brachiobasilic fistulas to patients prior to placing
it was easily obtainable, but also because it represents an upper arm graft.
time at risk for catheter-related complications such as bac-
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